• Aromatase Inhibition by Lamotrigine: Impacts on Steroidogene

  2026-07-22

  This study systematically investigates how lamotrigine and other antiepileptic drugs inhibit the human aromatase enzyme (CYP19), a key regulator of sex hormone synthesis. The findings provide detailed evidence of lamotrigine’s moderate inhibitory effect, with implications for endocrine health in epilepsy treatment and experimental research.

• Applied Use-Cases of (S)-1-(3-fluoro-4-(trifluoromethoxy)phe

  2026-07-22

  (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186) empowers researchers to dissect the Nrf2 signaling axis and osteoclast differentiation with high reproducibility. Its robust solubility and validated purity underpin advanced enzyme inhibition and redox studies in biochemical, cancer, and neuroscience research.

• UL84-FHL2 Axis in HCMV: Suppressing Interferon and Promoting

  2026-07-21

  Li et al. (2026) identify a novel immune evasion mechanism in human cytomegalovirus (HCMV), showing that the viral UL84 protein binds FHL2 to inhibit type I interferon (IFN-β) production and enhance viral replication. This discovery advances understanding of HCMV pathogenesis and opens avenues for targeting viral-host protein interactions.

• U0126: Selective MEK1/2 Inhibitor for MAPK/ERK Pathway Disse

  2026-07-21

  U0126 is a potent, selective MEK1/2 inhibitor used to dissect MAPK/ERK signaling in cellular models. It blocks MEK1/2 activity non-competitively, impacting downstream ERK1/2 phosphorylation and cellular fate. This article details its biological rationale, mechanism, evidence, and optimal research workflows.

• ERK5/MAPK Pathway in Vitamin D3-Induced AML Differentiation

  2026-07-20

  This study demonstrates that the ERK5/MAPK signaling pathway plays a critical and distinct role in mediating terminal differentiation of myeloid leukemia cells upon stimulation with 1α,25-(OH)2 vitamin D3. The findings reveal potential avenues for combinatorial therapies targeting MAPK sub-pathways in acute myeloid leukemia (AML), with implications for enhancing differentiation-based cancer treatments.

• Triptolide (PG490): Precision Tool for Translational Discove

  2026-07-20

  This thought-leadership article explores Triptolide (PG490) as a multifaceted molecular tool—delving into its mechanistic actions, translational impact, and strategic value for researchers in oncology, immunology, and developmental biology. Integrating foundational findings on genome activation and metastatic control, it provides actionable guidance on protocol design and positions Triptolide as an indispensable asset for high-precision experimental workflows.

• Ouabain as a Selective Na+/K+-ATPase Inhibitor: Mechanistic

  2026-07-19

  Discover how Ouabain, a selective Na+/K+-ATPase inhibitor, enables advanced mechanistic studies in ion transport and cardiac physiology. This article delivers original insight into assay design, translational research, and nuanced protocol optimization.

• Phosbind Acrylamide: Precision Phosphate-Binding Reagent for

  2026-07-18

  Phosbind Acrylamide transforms phosphorylation analysis by enabling high-resolution, antibody-free detection of protein phosphorylation states in SDS-PAGE workflows. Its unique phosphate-binding chemistry, optimal for the 30–130 kDa range, empowers signal transduction and kinase pathway studies with unmatched clarity and efficiency.

• Mc-Val-Cit-PABC-PNP: Technical Guidance for ADC Synthesis

  2026-07-17

  Mc-Val-Cit-PABC-PNP is a cathepsin B-cleavable ADC peptide linker designed for researchers developing antibody-drug conjugates requiring selective lysosomal payload release. Best suited for organic solvent-based workflows, it is not appropriate for aqueous, diagnostic, or clinical applications due to its solubility and intended use profile.

• EPZ5676: Potent DOT1L Inhibitor for MLL-Rearranged Leukemia

  2026-07-17

  EPZ5676 is a highly selective DOT1L inhibitor with nanomolar potency, enabling precise disruption of H3K79 methylation in MLL-rearranged leukemia models. Its exceptional selectivity and robust cytotoxicity in acute leukemia cell lines make it a cornerstone tool for histone methyltransferase inhibition assays. APExBIO provides EPZ5676 as a rigorously characterized research reagent.

• SCH772984: Redefining ERK1/2 Inhibition for Tumor Model Rese

  2026-07-16

  Explore the scientific foundations and experimental potential of SCH772984, a potent ERK1/2 inhibitor, in dissecting MAPK/ERK pathway inhibition and overcoming tumor radioresistance. This article delivers actionable insights for advanced cancer model design and translational research.

• SB 431542: Precision ALK5 Inhibition for Neuroinflammation R

  2026-07-16

  Explore the advanced use of SB 431542 as a potent ALK5 inhibitor for dissecting TGF-β signaling in neuroinflammation and Alzheimer’s research. This in-depth guide reveals unique scientific and experimental considerations, bridging molecular assay design with translational neuroscience.

• Vernakalant for Rapid Conversion of Atrial Fibrillation: Pha

  2026-07-15

  This phase 3, randomized, placebo-controlled trial demonstrates that vernakalant hydrochloride enables rapid and effective pharmacological conversion of recent-onset atrial fibrillation (AF) with a favorable safety profile. The findings highlight vernakalant's clinical potential as an alternative to electrical cardioversion and existing antiarrhythmic agents, streamlining acute AF management.

• Angiotensin II–HIF-1α Axis Regulates Ferroptosis and Radiore

  2026-07-15

  This study delineates how local angiotensin II (Ang II) suppresses ferroptosis and drives radioresistance in nasopharyngeal carcinoma (NPC) through the HIF-1α-HILPDA axis. The findings identify key molecular feedback loops and suggest that targeting both Ang II signaling and ferroptosis may enhance radiotherapy efficacy in NPC.

• Quaternization Enables Lung-Selective mRNA Delivery via Nano

  2026-07-14

  This study demonstrates that quaternization of lipid-like nanoassemblies transforms their organ tropism from spleen to lung, achieving over 95% mRNA expression in the lung after intravenous delivery. These findings offer a new chemical strategy for lung-targeted mRNA therapeutics, expanding the application scope of mRNA delivery systems beyond hepatic tissues.

16830 records 1/1122 page Next 12345 下5页 Last page